Table 1 Baseline characteristics of the patients included in the GIRAF trial. Data are depicted according to arm allocation for patients that completed the 2Â years cognitive assessment (mITT population, no imputation). Numbers indicate median (IQR) for non-normal continuous variables, mean (standard deviation) for continuous variables, and number (percentage) for dichotomous variables. Normality was assessed by a Shapiro-Wilks test at 5% significance
Characteristics | Dabigatran (n = 83) | Warfarin (n = 66) |
|---|---|---|
Age (years) | 74 (71 to 77) | 76 (72 to 77) |
Sex (male) | 51 (61.4%) | 39 (59.1%) |
Education (years) | 7 (4 to 12) | 4 (4 to 9) |
CHA2DS2-VASc median (IQR) | 4 (3 to 4) | 4 (3 to 5) |
HAS - BLED median (IQR) | 1 (1 to 1.25) | 1 (1 to 1) |
MMSE score | 27 (26 to 29) | 27 (26 to 29) |
MoCA score | 23 (19 to 25) | 22 (21 to 25) |
NTB score | 0.08 (0.60) | − 0.12 (0.58) |
CGNT score (composite score) | 0.24 (0.02 to 0.47) | − 0.04 (− 0.27 to 0.31) |
Hypertension | 72 (86.7%) | 60 (90.9%) |
Diabetes mellitus | 30 (36.1%) | 27 (40.9%) |
Dyslipidemia | 48 (57.8%) | 37 (56.1%) |
Tobacco (smoker + ex-smoker) | 43 (51.8%) | 30 (45.5%) |
Coronary artery disease | 18 (21.7%) | 16 (24.2%) |
Chronic heart failure | 33 (39.8%) | 32 (48.5%) |
Hypothyroidism | 25 (30.1%) | 13 (19.7%) |
Previous medications | ||
 Acetylsalicylic acid | 10 (12%) | 5 (7.6%) |
 Clopidogrel | 1 (1.2%) | 1 (1.5%) |
 ACEI | 24 (28.9%) | 20 (30.3%) |
 Angiotensin receptor blockers | 29 (34.9%) | 25 (37.9%) |
 Beta blockers | 60 (72.3%) | 50 (75.8%) |
 Calcium blocker | 12 (14.5%) | 10 (15.2%) |
 Antiarrhythmic | 8 (9.6%) | 5 (7.6%) |
 Digitalis | 9 (10.8%) | 2 (3%) |
 Diuretics | 39 (47%) | 35 (53%) |
 Statins | 55 (66.3%) | 46 (69.7%) |
 SSRI | 5 (6%) | 5 (7.6%) |